Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949219 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
A Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT02949219 is a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 41 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT02949219, a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
Study Locations (8)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic in Arizona - Scottsdale
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
South Dakota
- Rapid City Regional Hospital - Rapid City
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02949219
The ClinicalTrials.gov registry entry for NCT02949219 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Small Intestinal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02949219 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Arizona, District of Columbia, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02949219 about?
NCT02949219 is a clinical study titled "Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery". This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spre...
What is the current status of trial NCT02949219?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2017-03-24. Estimated completion is 2024-12-31.
What conditions does trial NCT02949219 study?
This clinical trial studies the following conditions: Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma.
What interventions are being tested in trial NCT02949219?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02949219?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02949219 being conducted?
This trial has 8 study locations across Arizona, District of Columbia, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Small Intestinal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Small Intestinal Adenocarcinoma
All registered trials for this condition
Recurrent Small Intestinal Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.